Biotechnology
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy
MELBOURNE, Australia and SAN FRANCISCO, June 23, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the Italian Medicin...
2022-06-23 23:00
2194
Berry Oncology launches HIFI Pan-Cancer Screening, a multi-cancer early screening product for detecting six high-risk cancers at one time
BEIJING, June 23, 2022 /PRNewswire/ -- On June 23, Berry Oncology, a global leading company specialized in genomic testing and early cancer screening, announced the launch of its innovative one-time precision product HIFI Pan-Cancer Screening, which is an early multi-cancer screening product ...
2022-06-23 22:39
2559
Viva Biotech Successfully Held The 3rd Annual Partnership Summit
SHANGHAI, June 23, 2022 /PRNewswire/ -- June 16th-20th, 2022 (Beijing time), Viva Biotech 2022 Partnership Summit was successfully held. Over 300 attendees joined the Summit, including founders from portfolio companies, representatives from global investment institutions, R&D heads from pharmaceu...
2022-06-23 20:30
2047
I-Mab Receives Top Rankings in Five Categories by Institutional Investor
GAITHERSBURG, Md. and SHANGHAI, June 23, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it was ranked among the top companies i...
2022-06-23 20:00
1365
Hyundai Mobis plans to extend biotech to mobility to take care of the driver's health
* The new healthcare tech 'Smart Cabin' controller that analyzes vital signs, such as posture, heart rate, and brainwaves, to help with safe driving. * Switches to autonomous driving when the driver is found to be stressed and manages the CO2 level in the cabin * Embedded technology that app...
2022-06-23 16:00
1653
Mojia Biotech Completes Series B Financing to Advance Manufacturing of Bio-based Materials
SHANGHAI, June 22, 2022 /PRNewswire/ -- Mojia Biotech, a Shanghai-based leading bio-manufacturing company dedicated to sustainable development and carbon neutrality, announced the completion of an $80 million Series B Financing. The funds will be used to commercialize its Viridimin™ brand of anim...
2022-06-23 09:00
1718
Sirnaomics to Present the Latest Developments of Dual-Targeted RNAi Therapeutics based on its Proprietary GalAhead™ Program at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium
GAITHERSBURG, Md. and SUZHOU, China, June 22, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that the Company's Chief Technology Officer,Dmitry Samarsky, Ph...
2022-06-22 00:29
2516
Scientists take the first step to master an all-powerful cell type in the beginning of life
Sheng Ding and his team at Tsinghua University School of Pharmaceutical Sciences publish innovative work in Nature BEIJING, June 21, 2022 /PRNewswire/ -- From cloning to regeneration, how to find alternative paths to create or rejuvenate life has been one of the big questions for biologists. It ...
2022-06-21 23:10
2178
3Z closes $2 million funding for preclinical development of novel ADHD and Insomnia therapeutics identified by 3Z´s zebrafish drug discovery platform
REYKJAVIK, Iceland, June 20, 2022 /PRNewswire/ -- 3Z, a Reykjavik based drug discovery company is pleased to announce the closure of a$2 million funding round led by seasoned investors in pharmaceuticals and medical technology. The just closed funding will accelerate finalization of preclinical s...
2022-06-20 21:01
1703
Acepodia Announces FDA Clearance of IND Application for ACE1831, an Anti-CD20 Armed Allogeneic gamma delta T-cell Therapy Candidate to Treat Patients with non-Hodgkin's Lymphoma
ACE1831 is a potential antibody‑armed allogeneic gamma delta T cell therapy developed using Acepodia's unique antibody-cell conjugation (ACC) technology as an optimized T cell engager platform to treat patients with non-Hodgkin's lymphoma ALAMEDA, Calif. and TAIPEI, Taiwan, June 20, 2022 /PRNews...
2022-06-20 20:00
1806
Onward Therapeutics Made a Second Strategic Equity Investment in Emercell for Their NK Cell Technology in Cancer Immunotherapy
EPALINGES, Switzerland and MONTPELLIER, France, June 20, 2022 /PRNewswire/ -- Onward Therapeutics SA (Onward Therapeutics) and Emercell SAS (Emercell) announced today the recent exercise of Onward Therapeutics' second of three instalments of equity investment in Emercell. With this investment, On...
2022-06-20 12:00
1762
2022 Tang Prize in Biopharmaceutical Science Honors Three Scientists for Developing COVID-19 mRNA Vaccines
TAIPEI, Taiwan , June 18, 2022 /PRNewswire/ -- After the 2014 and 2016 winners for the Tang Prize in Biopharmaceutical Sciences were crowned the Nobel Prize in 2018 and 2020 respectively, this category has continued to garner much attention worldwide. After much waiting, names of the latest winne...
2022-06-19 10:30
2941
2022 Tang Prize in Biopharmaceutical Science Honors Three Scientists for Developing COVID-19 mRNA Vaccines
TAIPEI, Taiwan, June 18, 2022 /PRNewswire/ -- After the 2014 and 2016 winners for the Tang Prize in Biopharmaceutical Sciences were crowned the Nobel Prize in 2018 and 2020 respectively, this category has continued to garner much attention worldwide. After much waiting, names of the latest winner...
2022-06-19 10:30
3019
US FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER
SYDNEY, June 17, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to Kazia's paxalisib for the treatmen...
2022-06-17 20:00
3591
Global Cord Blood Corporation Announced Cellenkos Receives FDA Clearance of IND Application for CK0804 as Add on Therapy to Ruxolitinib for the Treatment of Myelofibrosis
HONG KONG, June 17, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, is pleased to announce that Cellenkos, Inc. ("CLNK"...
2022-06-17 04:20
2837
Insilico Medicine appoints Dr. Feng Ren as co-CEO
Dr. Feng Ren, Chief Scientific Officer (CSO) and head of global research and development is named co-CEO of Insilico Medicine Highlights: * Insilico Medicine is a global, end-to-end, fully-integrated AI-powered biotechnology company with three business models: AI platform, collaboration, and ...
2022-06-16 21:03
3553
Global Cord Blood Corporation Announces Purported EGM Is Not Validly Convened
HONG KONG, June 16, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO, "GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, noticed that onJune 3, 2022 Blue Ocean Structure Inv...
2022-06-16 20:30
4234
Global Pharmaceutical Market Drives Innovative Digitalization to Accelerate Drug Discovery
According to Frost & Sullivan, digitalization across the pharmaceutical value chain will improve the industry´s efficiency. SAN ANTONIO, June 16, 2022 /PRNewswire/ -- Frost & Sullivan's recent analysis, Global Pharmaceuticals Outlook, finds that the accelerated drug development timelines are driv...
2022-06-16 15:12
1950
Sirnaomics Announces Publication of STP705 Clinical Study Results for Treatment of isSCC in the Peer-Reviewed Journal of Drugs in Dermatology
GAITHERSBURG, Md. and SUZHOU, China, June 16, 2022 /PRNewswire/ -- Sirnaomics Ltd. ("Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the peer-reviewed publication of Phase IIa clinical study results of its lead th...
2022-06-16 13:01
2165
GILEAD SCIENCES NEW DATA HIGHLIGHTS PEOPLE LIVING WITH HIV WHO ARE VIRALLY SUPPRESSED EXPERIENCE SIMILAR HEALTH-RELATED QUALITY OF LIFE AS GENERAL POPULATION
– Data in Taiwan Shows That Antiretroviral Therapies Have Helped Transform HIV Into a Chronic Condition and Bring Positive Change in the Outlook for People Living with HIV– SINGAPORE, June 16, 2022 /PRNewswire/ -- Gilead Sciences, Inc. today announced results from an online survey that assessed ...
2022-06-16 11:15
2295
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 287 media titles]
2024-04-30 10:11
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 274 media titles]
2024-04-24 17:09
Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39
Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
[Picked up by 268 media titles]
2024-04-24 13:00
Most Read
Automation Anywhere Appoints Tim McDonough as Chief Marketing Officer to Drive Global Awareness and Growth for the Leader in AI-Powered Automation
2024-04-24 03:57
7862
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
2024-04-24 17:09
6955
Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
2024-04-24 13:00
4242
Scienjoy Holding Corporation Reports Fiscal Year 2023 Financial Results
2024-04-27 04:30
2819